Joy Jean Campbell

US Patent:

20110135581, Jun 9, 2011

Filed:

May 22, 2009

Appl. No.:

12/992913

Inventors:

Eric Weaver - Ankeny IA, US
Joy Campbell - Ankeny IA, US
Louis Russell - Ankeny IA, US
Miquel Moreto Pedragosa - Barcelona, ES
Anna Perez-Bosque - Barcelona, ES
Francisco Javier Polo Pozo - Barcelona, ES
Joseph Crenshaw - Ankeny IA, US

Assignee:

THE LAURIDSEN GROUP, INC. - Ankeny IA

International Classification:

A61K 39/395
A61K 9/12
A61P 11/00
A61P 11/06
A61P 37/00

US Classification:

424 45, 4241301

Abstract:

The present invention provides methods for reducing, attenuating, diminishing, preventing or inhibiting pulmonary inflammation in an animal by orally administering a plasma fraction to said animal prior to or following exposure or challenge of the animal to an endotoxin.

US Patent:

20210260112, Aug 26, 2021

Filed:

May 17, 2018

Appl. No.:

16/613951

Inventors:

- Granollers, ES
Louis Edward RUSSELL - Ankeny IA, US
María Carmen RODRÍGUEZ CANEL - Barcelona, ES
Joy Marlene CAMPBELL - Ames IA, US
Joe David CRENSHAW - Windsor Heights IA, US
Miquel MORETÓ PEDRAGOSA - Esplugues del Llobregat, ES
Anna PÉREZ BOSQUE - Igualada, ES
Lluïsa MIRÓ MARTÍ - Barcelona, ES

Assignee:

APC EUROPE SLU - Granollers

International Classification:

A61K 35/16
A61K 35/57
A61K 38/40
A61K 38/17
A61P 25/28

Abstract:

The present application relates to the administration of plasma, fractions thereof, or mixtures thereof to humans or animals to treat or otherwise improve cognitive impairment disorders, including dementia (e.g., vascular dementia, dementia with Lewy bodies, dementia resulting from Alzheimer's disease, dementia resulting from Parkinson's disease, frontotemporal dementia, and dementia resulting from normal pressure hydrocephalus in humans, and cognitive dysfunction syndrome in companion animals), concussion, and traumatic brain injury, in certain embodiments, the invention comprises a method of treating a cognitive impairment disorder in a human or companion animal subject, said method comprising: administering to said subject one or more cognitive functioning tests to identify a subject suffering from a cognitive impairment disorder; and administering to said subject a therapeutically effective amount of an animal plasma composition; wherein said administration provides an improvement in said subject's results in said one or more cognitive impairment tests.